Principle Investigator: Ellen Mowry, M.D.
For more information, please email: firstname.lastname@example.org
Dr. Ellen Mowry is currently recruiting subjects for a study that will assess the effectiveness of vitamin D supplementation in patients with multiple sclerosis (MS). This trial is being done because previous studies of vitamin D levels in people with MS show that those with lower vitamin D levels are more likely to have MS attacks and new MS lesions develop on brain MRI, but it is not known if giving vitamin D supplements reduces the amount of MS activity.
This is a multicenter trial in which participants with relapsing-remitting MS will be receive high-dose or low-dose vitamin D for two years. All participants will be given glatiramer acetate (Copaxone) for free during the study. The purpose of the study is to assess if vitamin D is effective in reducing relapses and new MRI lesions in people with multiple sclerosis.
In order to be eligible, participants must have relapsing-remitting MS who have had a certain number of relapses and new MRI lesions in the past one to two years. They must have no limitations in walking because of the MS. Participants must be aged 18 to 50. They must not have received Copaxone for more than 3 months in the past. They must not have been on natalizumab (Tysabri), fingolimod (Gilenya), or fumarate in the past six months and cannot have received any other unapproved MS therapy or chemotherapy. Participants must not have taken more than 1,000 IU/day of vitamin D3 in the three months before the first study visit. Those with certain other health conditions or taking certain medications will be excluded for the sake of safety.